article thumbnail

Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade

Pharmaceutical Technology

Amid President Donald Trump’s stated desire to sharply reduce drug prices on the US market, India has also proposed to supply generic medicines at between 20% and 25% of the current reference branded prices, for three years after originator patent expiry.

article thumbnail

Sinking prices for generic meds a major factor in US shortage crisis: report

Fierce Pharma

drug shortages, a new white paper from German market analytics firm QYOBO supports the thesis that disproportionately low prices for generic medicines can make it difficult for drugmakers to keep supplies afloat. As lawmakers and industry groups seek to get a handle on U.S. |

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pathbreakers: The journey of first generics

Pharmaceutical Technology

In recent years, first generics have improved patient access to essential treatments and offered affordable treatment options for patients with multiple sclerosis, asthma, heart disease, diabetes, and even the flu. However, business and other considerations may have an impact on how quickly a generic becomes available.

FDA 98
article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

Joy Polefrone, the executive director of the organization, says it aims to build a cluster of partners who are capable of manufacturing generic medicines. The US Department of Commerce’s Economic Development Administration (EDA) awarded the organization $52.9 million as part of the Build Back Better Regional Challenge.